Bcl-2 pathway inhibition in solid tumors: a review of clinical trials

Ploumaki, Ioanna; Triantafyllou, Efthymios; Koumprentziotis, Ioannis-Alexios; Karampinos, Konstantinos; Drougkas, Konstantinos; Trontzas, Ioannis; Karavolias, Ioannis; A. Kotteas, Elias.
Clin. transl. oncol. (Print) ; 25(6): 1554-1578, jun. 2023. ilus
Artículo en Inglés | IBECS (España) | ID: ibc-221190

Documentos relacionados

  1. Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain.
  2. Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers.
  3. B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy.
  4. Getting more bang for their buck: BCL2 inhibitors boost dendritic-cell function to enhance anti-cancer immune surveillance.
  5. Development of venetoclax performance using its new derivatives on BCL-2 protein inhibition.
  6. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.
  7. Targeting Apoptosis in Cancer.
  8. Why anti-Bcl-2 clinical trials fail: a solution.
  9. Last but not least: BFL-1 as an emerging target for anti-cancer therapies.
  10. Comprehensive review of Bcl-2 family proteins in cancer apoptosis: Therapeutic strategies and promising updates of natural bioactive compounds and small molecules.